Phase 1 Study of BG-C477 Alone and with Other Cancer Treatments in Adults With Advanced Solid Tumors

What this Trial Is About

Researchers are evaluating BG-C477, a potential anticancer drug, for its safety, tolerability, how it is processed by the body, and its preliminary activity against advanced solid tumors. This phase 1ab, open-label study will test BG-C477 alone and in combination with other anticancer agents, including chemotherapy and tislelizumab, in participants with certain advanced solid tumors. The study is sponsored by BeOne Medicines and aims to find safe dose levels and early signals of the drugs effect on tumors. Participants will receive BG-C477 intravenously either as monotherapy in sequential dose escalation cohorts or in combination with other anticancer agents. The study includes different phases Phase 1a focuses on dose escalation and safety expansion, while Phase 1b involves dose optimization and combination therapy expansion. Dose levels that are found safe will be further evaluated, and treatment continues according to the assigned cohort and dose schedule. Participants will be closely monitored throughout the study for adverse events, drug levels in the blood, and tumor responses using standard criteria. Safety assessments will continue up to 30 days after the last dose, with some measures tracked for up to two years. Evaluations include measuring overall response rates, progression-free survival, and immune responses to the drug. The total participation duration varies with study phase and treatment response, with regular visits for treatment administration and monitoring.

A Study of BG-C477 in Participants With Advanced Solid Tumors